Major companies in atopic dermatitis: Key industry players driving the field of atopic dermatitis treatment include Eli Lilly and Company, AbbVie, LEO Pharma, Insight Corporation, Arena Pharmaceuticals, Oneness Biotech, Galderma, DS Biopharma, Janssen, AOBiome Therapeutics, Sanofi/Regeneron Pharmaceuticals, RAPT Therapeutics, Pfizer, Japan Tobacco, Torii Pharmaceutical, Kymab, Qurient, Arcutis Biotherapeutics, Cara Therapeutics, Vanda Pharmaceuticals among others.

Atopic Dermatitis Market Insights

(Albany, USA)– DelveInsight’s “Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast – 2034” provides a comprehensive understanding of atopic dermatitis along with historical and projected epidemiological trends in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan.

The report provides insights into current treatment paradigms, emerging therapeutic approaches, market shares of existing treatments, and the expected atopic dermatitis market size from 2020 to 2034. It also outlines the treatment algorithm, key drivers and barriers, unmet clinical needs, and potential growth opportunities for the sector.

? Request a sample here: Atopic dermatitis market forecast

Atopic Dermatitis Market Report Highlights

• DelveInsight predicts a significant CAGR growth for the atopic dermatitis market through 2034.
  
  
• The overall 7MM atopic dermatitis market size is expected to be valued at approximately USD 17 billion in 2023 and grow steadily through 2034.
  
  
• Key market participants include Sanofi/Regeneron, Pfizer, Eli Lilly, AbbVie, LEO Pharma, Galderma, and others.
  
  
• Several promising pipeline therapies are in various stages of development, including baricitinib, si-544, lebrikizumab, MEDI9929, dupilumab, midazolam, omeprazole and emollients.
  
  

Recent Updates and Trials (2024)

• Corvus PharmaceuticalsShared positive interim Phase I data for sokeritinib in moderate-to-severe Alzheimer's disease, demonstrating safety and efficacy in ITK inhibition.
  
  
• Concerto BioscienceStart of Phase I study of ENS-002, a live biologic targeted therapyStaphylococcus aureus, a major contributor to AD.
  
  
• Eli LillyResults from the Phase IIIb ADapt study showed that EBGLYSS achieved significant improvement in patients not responding to dupilumab.
  
  
• GaldermaLong-term data from the ARCADIA and OLYMPIA programs for nemolizumab are expected to be presented at the EADV Congress in 2024.
  
  
• Link Pharmaceuticalsshowed positive results in a Phase Ib trial of topical LNK01004 in mild-to-moderate Alzheimer's disease.
  
  

In 2023, the United States will hold the top market share for AD, followed by Japan.

Epidemiology of Atopic Dermatitis (2023)

• Diagnosed cases: 53.3 million overall, about 7MM.
  
  
• Widespread cases: Approximately 72.4 million in total.
  
  
• Gender distribution: Approximately 23.5 million men and 29.9 million women have been diagnosed.
  
  
• These figures are projected to increase through 2034 due to increased awareness and diagnostic efforts.
  
  

Treatment options and current drug status

DUPIXENT remains the top-selling treatment, generating $2 billion annually, especially among moderate to severe patients. Treatment options in Japan mirror those in the US and EU5 and include DUPIXENT, RINVOQ, CIBINQO, ADBRY/ADTRALZA, CORECTIM, OLUMIANT, MOIZERTO, and MITCHGA.

Notable exams for April 2024:

• Suzhou Zelgen BiopharmaceuticalsA Phase I/II trial evaluating yaktinib hydrochloride cream has begun.
  
  
• PfizerThe company has initiated a Phase 2 trial of PF-07275315 and PF-07264660 in adults with moderate to severe Alzheimer's disease.
  
  
• Eli Lillyinitiated an open-label study evaluating lebrikizumab in dupilumab-experienced patients with Alzheimer's disease.
  
  

? Learn more about a treatment poised to lead the market: Outlook for the Atopic Dermatitis Market

Understanding Atopic Dermatitis

Atopic dermatitis (AD), also known as eczema, is a chronic skin disease characterized by dryness, inflammation, and persistent pruritus. It primarily affects children, but can also occur in adults. Its pathophysiology involves immune dysregulation, environmental factors, and skin barrier dysfunction.

Common symptoms include red, scaly patches, exudation, and intense itching, often leading to scratching and secondary infection. It frequently occurs in conjunction with asthma and allergic rhinitis, collectively forming the "atopic triad."

Treatment strategiesMoisturizers, corticosteroids, calcineurin inhibitors, and systemic biologics are common interventions. Advanced therapies target specific immune pathways (e.g., IL-4, IL-13, JAK-STAT).

Epidemiological breakdown of atopic dermatitis

• Total disease-affected population
  
  
• Diagnosed cases
  
  
• Severity distribution (adult vs. pediatric)
  
  
• Gender-Based Incidence
  
  
• Prevalence of chronic pruritus
  
  

? Download the full report to explore epidemiological drivers: Trends in the Atopic Dermatitis Market

Leading Pipeline Therapies

Loccatinlimab (KHK4083/AMG 451) – Amgen/Kyowa Kirin
This anti-OX40 monoclonal antibody is designed to target pathogenic T cells and is currently undergoing Phase III evaluation (ROCKET program) in patients with moderate to severe Alzheimer's disease.

Other emerging agents include:

• Lebrikizumab– Eli Lilly
  
  
• Nemolizumab– Galderma
  
  
• Zifamilast– Otsuka Pharmaceutical
  
  
• From Roflumilast– Arctis Biotherapeutics
  
  

Mid-stage development includes FB825 (Oneness Biotech), B244 (AOBiome), etrasimod (Arena), KY1005 (Kymab), DS107 (DS Biopharma), Q301 (Qurient), and bermekimab (Janssen).

? Learn more about future treatments: Clinical trials and advances in atopic dermatitis

Market Trends

The atopic dermatitis market is expected to witness significant growth due to novel MOAs such as JAK inhibitors (oral/topical), PDE inhibitors, IL-13 inhibitors, leukotriene inhibitors, KOR/NK-1 antagonists, etc. Increased awareness, reimbursement models, and access to healthcare are further driving the adoption of advanced therapies.

? Explore more treatment options: Atopic dermatitis treatment market

Scope of the report

• Target area: US, EU5, Japan (7MM)
  
  
• Featured companies: Sanofi, Regeneron, Pfizer, Japan Tobacco, Torii, Eli Lilly, AbbVie, LEO Pharma, Incyte, Galderma, Janssen, Arena, etc.
  
  
• Pipeline Therapies: Baricitinib, dupilumab, lebrikizumab, etc.
  
  
• Market Scene: Insights into drivers, barriers and future growth.
  
  

table of contents

1. Key highlights
   
   
2. Report Introduction
   
   
3. Market Overview
   
   
4. Epidemiology methodology
   
   
5. Background of the disease
   
   
6. Epidemiological insights
   
   
7. The patient journey
   
   
8. Clinical Trial Endpoints
   
   
9. Over-the-counter medications
   
   
10. Pipeline Drugs
    
    
11. 7MM Market Analysis
    
    
12. Access and Refunds
    
    
13. KOL Perspective
    
    
14. SWOT Analysis
    
    
15. Unmet needs
    
    
16. appendix
    
    
17. DelveInsight Service
    
    
18. Disclaimer
    
    

About DelveInsight

DelveInsight is a leading provider of life sciences market intelligence and consulting services, known for its in-depth syndicated research and customized business solutions across the healthcare market.